We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Gives Green Light to AstraZeneca’s Tagrisso
The FDA has approved AstraZeneca’s metastatic non-small cell lung cancer drug Tagrisso in a first-of-its-kind indication targeting patients with the EGFR T790M mutation.